Enter Your Search:
Results 1-2 (2)
Go to page number:
Select a Filter Below
Investigational New Drugs (1)
Journal of Osteoporosis (1)
van den Borne, Ben E. E. M. (2)
Beijer, Sandra (1)
Dagnelie, Pieter C. (1)
Gielisse, Eric A. R. (1)
Graat-Verboom, Lidwien (1)
Hupperets, Pierre S. (1)
Nijziel, Marten R. (1)
Smeenk, Frank W. J. M. (1)
Spruit, Martijn A. (1)
Wouters, Emiel F. M. (1)
van Henten, Arjen M. J. (1)
van den Beuken-van Everdingen, Marieke (1)
Year of Publication
Whole-Body versus Local DXA-Scan for the Diagnosis of Osteoporosis in COPD Patients
Spruit, Martijn A.
Smeenk, Frank W. J. M.
Wouters, Emiel F. M.
Journal of Osteoporosis
Background. Osteoporosis is an extrapulmonary effect of chronic obstructive pulmonary disease (COPD). Diagnosis of osteoporosis is based on BMD measured by DXA-scan. The best location for BMD measurement in COPD has not been determined. Aim of this study was to assess whole-body BMD and BMD of the hip and lumbar spine (local DXA) in COPD patients and compare the prevalence of osteoporosis at these locations. Methods. Whole body as well as local DXA-scan were made in 168 COPD patients entering pulmonary rehabilitation. Patient-relevant characteristics were assessed. Prevalence of osteoporosis was determined. Characteristics of patients without osteoporosis were compared to patients with osteoporosis on local DXA. Results. A higher prevalence of osteoporosis was found using local DXA compared to whole-body DXA (39% versus 21%). One quarter of patients without osteoporosis on whole body-DXA did have osteoporosis on local DXA. Significant differences in patient characteristics between patients without osteoporosis based on both DXA measurements and patients with osteoporosis based on local DXA only were found. Conclusions. DXA of the hip and lumbar spine should be made to assess bone mineral density in COPD patients. The lowest T-score of these locations should be used to diagnose osteoporosis.
Intravenous ATP infusions can be safely administered in the home setting: a study in pre-terminal cancer patients
Gielisse, Eric A. R.
Hupperets, Pierre S.
van den Beuken-van Everdingen, Marieke
Nijziel, Marten R.
van Henten, Arjen M. J.
Dagnelie, Pieter C.
Investigational New Drugs
The aim of the study was to investigate the safety of adenosine 5′-triphosphate (ATP) administration at home in pre-terminal cancer patients. Included were patients with cancer for whom medical treatment options were restricted to supportive care, who had a life expectancy of less than 6 months, a World Health Organization performance status 1 or 2, and suffered from at least one of the following complaints: fatigue, anorexia or weight loss >5% over the previous 6 months. Side effects were registered systematically on a standard form according to the National Cancer Institute (NCI) Common Toxicity Criteria. Fifty-one patients received a total of 266 intravenous ATP infusions. Of these, 11 infusions (4%) were given at the lowest dose of 20 μg kg−1 min−1, 85 infusions (32%) at 25–40 μg kg−1 min−1, and 170 (64%) at the highest dose of 45–50 μg kg−1 min−1 ATP. The majority of ATP infusions (63%) were without side effects. Dyspnea was the most common side effect (14% of infusions), followed by chest discomfort (12%) and the urge to take a deep breath (11%). No symptoms of cardiac ischemia occurred in any of the infusions. All side effects were transient and resolved within minutes after lowering the ATP infusion rate. Side effects were most frequent in the presence of cardiac disorders. We conclude that ATP at a maximum dose of 50 μg kg−1 min−1 can be safely administered in the home setting in patients with pre-terminal cancer.
ATP; Side effects; Pre-terminal cancer; Home-infusion
Results 1-2 (2)
Go to page number:
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
Canada Institute for Scientific and Technical Information
in cooperation with the
National Center for Biotechnology Information
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.